In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling
Restricted accessOtherFirst published online August, 2007
In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling
Aripiprazole, (+)terguride, OPC-4392 and (—)3-PPP have been classified as dopamine D2 receptor partial agonists based largely on their activity in second messenger-based assays of dopamine D2 receptor signalling. Nevertheless, signal transduction amplification might result in these compounds behaving as dopamine D2 receptor full agonists at a more downstream level of signalling. We compared the intrinsic activity (Emax, expressed as a percentage of the maximal effect of dopamine) of aripiprazole, (+)terguride, OPC-4392 and (—)3-PPP using second (calcium (Ca2+) mobilization) and third (extracellular signal-regulated kinase 2 (ERK2) phosphoprotein expression) messenger readouts of cloned human dopamine D2long (hD2L) receptor signalling in CHO cells. These compounds were all less potent and displayed lower intrinsic activity in the Ca2+ assay (aripiprazole = 24.3%, (+)terguride = 56.9%, OPC-4392 = 58.6% and (—)3-PPP = 75.1%), and aripiprazole (Emax = 54.5%) displayed a substantially lower intrinsic activity than (+)terguride (Emax = 92.3%), OPC-4392 (Emax = 93.1%) and (—)3-PPP (Emax = 101.1%) in the more downstream-based ERK2 phosphoprotein expression assay. These drug effects on Ca2+ mobilization and ERK2 phosphoprotein expression were mediated through dopamine hD2L receptors, as they all were blocked by (—)raclopride, whereas (—)raclopride and other dopamine D2 receptor antagonists (haloperidol, risperidone, ziprasidone, olanzapine, clozapine and quetiapine) were inactive on their own in both assays. These data are consistent with clinical evidence that only dopamine D2 receptor partial agonists with a sufficiently low enough intrinsic activity will prove effective against the positive symptoms of schizophrenia, and also highlight the importance of using downstream-based assays in the discovery of novel D2 receptor partial agonist therapeutics.
Baker J.G., Hall I.P., Hill S.J. (2003) Influence of agonist efficacy and receptor phosphorylation on antagonist affinity measurements: differences between second messenger and reporter gene responses. Mol Pharmacol64: 679—688
2.
Benkert O., Muller-Siecheneder F., Wetzel H. (1995) Dopamine agonists in schizophrenia: a review. Eur Neuropsychopharmacol5 (suppl.): 43—53
3.
Browning J.L., Patel T., Brandt P.C., Young K.A., Holcomb L.A., Hicks P.B. (2005) Clozapine and the mitogen-activated protein kinase signal transduction pathway: implications for antipsychotic actions. Biol Psychiatry57: 617—623
4.
Burris K.D., Molski T.F., Xu C., Ryan E., Tottori K., Kikuchi T., Yocca F.D., Molinoff P.B. (2002) Aripiprazole, a novel antipsychotic, is a highaffinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther302: 381—389
5.
Byars A., Burris K., Jordan S., Tottori K., Kikuchi T., McQuade R. (2002) Aripiprazole: a dopamine-serotonin system stabilizer . Eur Neuropsychopharmacol12 (suppl. 3): S290
6.
Chen J., Shen C., Meller E. (2002) 5-HT(1A) receptor-mediated regulation of mitogen-activated protein kinase phosphorylation in rat brain. Eur J Pharmacol452: 155—162
7.
Choi E.Y., Jeong D.W., Park K.W., Baik J.H. (1999) G protein-mediated mitogen-activated protein kinase activation by two dopamine D2 receptors. Biochem Biophys Res Commun256: 33—40
8.
Clark D., Hjorth S., Carlsson A. (1985a) Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. II. Theoretical considerations. J Neural Transm62: 171—207
9.
Clark D., Hjorth S., Carlsson A. (1985b) Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence. J Neural Transm62: 1—52
10.
Cosi C., Waget A., Rollet K., Tesori V., Newman-Tancredi A. (2005) Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT(1A) receptor activation. Brain Res1043: 32—41
11.
Cussac D., Duqueyroix D., Newman-Tancredi A., Millan M.J. (2002) Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h) serotonin (5-HT)(1A) receptors . Psychopharmacology162: 168—177
12.
Dean B., Scarr E. (2004) Antipsychotic drugs: evolving mechanisms of action with improved therapeutic benefits. Curr Drug Targets CNS Neurol Disord3: 217—225
13.
Fujikawa M., Nagashima M., Inoue T., Yamada K., Furukawa T. (1996) Partial agonistic effects of OPC-14597, a potential antipsychotic agent, on yawning behavior in rats. Pharmacol Biochem Behav53: 903—909
Hernandez-Lopez S., Tkatch T., Perez-Garci E., Galarraga E., Bargas J., Hamm H., Surmeier D.J. (2000) D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade. J Neurosci20: 8987—8995
16.
Jomphe C., Tiberi M., Trudeau L.E. (2006) Expression of D2 receptor isoforms in cultured neurons reveals equipotent autoreceptor function. Neuropharmacology50: 595—605
17.
Jordan S., Koprivica V., Chen R., Tottori K., Kikuchi T., Altar C.A. (2002) The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol441: 137—140
18.
Jordan S., Koprivica V., Dunn R., Tottori K., Kikuchi T., Altar C.A. (2004a) In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol483: 45—53
19.
Jordan S., Chen R., Johnson J., Regardie K., Whitehead R., Tadori Y., McQuade R., Kikuchi T. (2004b) Guanosine-5'-O-(3-[35S]thio)-triphosphate binding assays can be insensitive in detecting D2 partial agonist drug activity. Int J Neuropsychopharmacol7(suppl. 1): S263
20.
Jordan S., Chen R., Fernalld R., Johnson J., Regardie K., Kambayashi J., Tadori Y., Kitagawa H., Kikuchi T. (2006) In vitro biochemical evidence that the psychotomimetics phencyclidine, ketamine and dizocilpine (MK-801) are inactive at cloned human and rat dopamine D(2) receptors. Eur J Pharmacol540: 53—56
21.
Kane J.M., Carson W.H., Saha A.R., McQuade R.D., Ingenito G.G., Zimbroff D.L., Ali M.W. (2002) Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder . J Clin Psychiatry63: 763—771
22.
Kikuchi T., Tottori K., Uwahodo Y., Hirose T., Miwa T., Oshiro Y., Morita S. (1995) 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther274: 329—336
23.
Kontkanen O., Toronen P., Lakso M., Wong G., Castren E. (2002) Antipsychotic drug treatment induces differential gene expression in the rat cortex. J Neurochem83: 1043—1053
24.
Kyosseva S.V. (2004) Mitogen-activated protein kinase signaling. Int Rev Neurobiol59: 201—220
25.
Lahti R.A., Figur L.M., Piercey M.F., Ruppel P.L., Evans D.L. (1992) Intrinsic activity determinations at the dopamine D2 guanine nucleotide-binding protein-coupled receptor: utilization of receptor state binding affinities. Mol Pharmacol42: 432—438
26.
Lahti A.C., Weiler M.A., Corey P.K., Lahti R.A., Carlsson A., Tamminga C.A. (1998) Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia . Biol Psychiatry43: 2—11
27.
Lawler C.P., Prioleau C., Lewis M.M., Mak C., Jiang D., Schetz J.A., Gonzalez A.M., Sibley D.R., Mailman R.B. (1999) Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology20: 612—627
28.
Lee S.P., So C.H., Rashid A.J., Varghese G., Cheng R., Lanca A.J., O'Dowd B.F., George S.R. (2004) Dopamine D1 and D2 receptor co-activation generates a novel phospholipase C-mediated calcium signal. J Biol Chem279: 35671—35678
29.
Lu X.H., Dwyer D.S. (2005) Second-generation antipsychotic drugs, olanzapine, quetiapine, and clozapine enhance neurite outgrowth in PC12 cells via PI3K/AKT, ERK, and pertussis toxin-sensitive pathways. J Mol Neurosci27: 43—64
30.
Lu X.H., Bradley R.J., Dwyer D.S. (2004) Olanzapine produces trophic effects in vitro and stimulates phosphorylation of Akt/PKB, ERK1/2, and the mitogen-activated protein kinase p38. Brain Res1011: 58—68
31.
Meller E., Bohmaker K., Namba Y., Friedhoff A.J., Goldstein M. (1987) Relationship between receptor occupancy and response at striatal dopamine autoreceptors. Mol Pharmacol31: 592—598
32.
Meltzer H.Y., Stahl S.M. (1976) The dopamine hypothesis of schizophrenia: a review . Schizophr Bull2: 19—86
33.
Neve K.A., Seamans J.K., Trantham-Davidson H. (2004) Dopamine receptor signaling. J Recept Signal Transduct Res24: 165—205
34.
Pliska V. (1999) Partial agonism: mechanisms based on ligand-receptor interactions and on stimulus-response coupling. J Recept Signal Transduct Res19: 597—629
35.
Pozzi L., Hakansson K., Usiello A., Borgkvist A., Lindskog M., Greengard P., Fisone G. (2003) Opposite regulation by typical and atypical antipsychotics of ERK1/2, CREB and Elk-1 phosphorylation in mouse dorsal striatum. J Neurochem86: 451—459
36.
Reynolds G.P. (2004) Receptor mechanisms in the treatment of schizophrenia . J Psychopharmacol18: 340—345
37.
Richelson E., Souder T. (2000) Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci68: 29—39
38.
Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.X., Sibley D.R., Roth B.L., Mailman R. (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology28: 1400—1411
39.
Sweatt J.D. (2001) The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J Neurochem76: 1—10
40.
Tadori Y., Miwa T., Tottori K., Burris K.D., Stark A., Mori T., Kikuchi T. (2005) Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. Eur J Pharmacol515: 10—19
41.
Takeuchi Y., Fukunaga K. (2003) Differential regulation of NF-kappaB, SRE and CRE by dopamine D1 and D2 receptors in transfected NG108-15 cells. J Neurochem85: 729—739
42.
Tamminga C.A. (2002) Partial dopamine agonists in the treatment of psychosis . J Neural Transm109: 411—420
43.
Vanhoose A.M., Emery M., Jimenez L., Winder D.G. (2002) ERK activation by G-protein-coupled receptors in mouse brain is receptor identityspecific. J Biol Chem277: 9049—9053
44.
Yan Z., Feng J., Fienberg A.A., Greengard P. (1999) D(2) dopamine receptors induce mitogen-activated protein kinase and cAMP response element-binding protein phosphorylation in neurons. Proc Natl Acad Sci USA96: 11607—11612
45.
Yokoo H., Goldstein M., Meller E. (1988) Receptor reserve at striatal dopamine receptors modulating the release of [3H]dopamine. Eur J Pharmacol155: 323—327
